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68Objectives: This investigation compared patients undergoing lobectomy for non–small cell lung cancer by
either a general surgeon or a cardiothoracic surgeon across a geographically diverse system of hospitals to
see whether a significant difference in quality or cost was present.
Methods: The Premiere administrative database and tumor registry data of a single health system’s hospitals
was used to compare adherence to national treatment guidelines, patient outcomes, and charges for patients un-
dergoing lobectomy for non–small cell lung cancer in a 5-year period. Surgeons performing lobectomy were
designated as a general surgeon or cardiothoracic surgeon according to their national provider number and board
certification status. Excluded from analysis were centers that performed fewer than 50 lobectomies during the
study period.
Results: During the study period, 2823 lobectomies were performed by 46 general surgeons and 3653 lobecto-
mies were performed by 29 cardiothoracic surgeons in 54 hospitals in a single health care system. Significant
differences were found between general and cardiothoracic surgeons with respect to adherence to national guide-
lines in staging and treatment, mean length of stay, significant morbidity, and operative mortality. Mean charges
for lobectomy of the lung were also found to differ significantly between general and cardiothoracic surgeons.
Conclusions: This review found that currently measurable indicators for quality of care were significantly
superior and overall charges were significantly reduced when a lobectomy for non–small cell lung cancer
was performed by a cardiothoracic surgeon rather than by a general surgeon. (J Thorac Cardiovasc Surg
2013;145:68-74)According to some estimates, the majority of lung resec-
tions in the United States continue to be performed by gen-
eral surgeons.1 Other surgical specialties have found that
surgeons with additional formal training after general sur-
gery residency achieve superior outcomes in more complex
surgical procedures relative to general surgeons.2,3 Several
investigations have assessed the issue of whether a similar
variation in results exists between residency-trained cardio-
thoracic surgeons and general surgeons.1,4-6 Although these
authors have been able to show variation in such things as
preoperative and intraoperative staging, long-term survival,
and operative mortality, these analyses are limited because
of the use of a combination of claims or nonconsecutive
sampling databases, case mix designation of surgeon spe-
cialty rather than board certification, or the inclusion of
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The Journal of Thoracic and Cardiovascular Surgeno attempt at comparing the costs of care between the two
surgical specialties has been made. The purpose of this in-
vestigation was to compare the adherence to nationally ac-
cepted treatment guidelines, outcomes, and associated costs
for lobectomy of the lung for non–small cell lung cancer
(NSCLC) between general surgeons and thoracic surgeons
within a diverse health care system.MATERIALS AND METHODS
This study was designed as a retrospective cohort analysis. Institutional
review board approval was obtained at St Vincent Hospital (Indianapolis,
Ind) and individual patient consent was not required with the condition
of patient anonymity outside the initial data-gathering phase of the study.
By interrogating the Premier inpatient database (Premier Inc, Charlotte,
NC), hospitals performing at least 50 lobectomies (cumulative; Current
Procedural Terminology [CPT] code 32480) for NSCLC (International
Classification of Diseases, Ninth Revision [ICD-9] diagnosis codes
162.2, 162.3, 162.4, 162.5, 162) during the calendar years 2005 through
2009 within the Ascension Health system were identified. Lobectomy pro-
cedures were then attributed to individual surgeons within these facilities.
Surgeons were identified as either a general surgeon or a thoracic surgeon
on the basis their national provider numbers and their board certification
status. No attempt was made to differentiate thoracic surgeons who prac-
ticed cardiac and thoracic surgery from those that limited their practice
to noncardiac thoracic surgery.
Patient demographic data; adherence to National Comprehensive Can-
cer Network (NCCN) guideline7; and information related to the lobectomy
procedure, including charges, postoperative stay, operative morbidities,
and operative mortality were abstracted for each patient from the Premier
database or the local hospital’s American College of Surgeons tumorry c January 2013
Abbreviations and Acronyms
NCCN ¼ National Comprehensive Cancer
Network
NSCLC ¼ non–small cell lung cancer
Freeman et al General Thoracic Surgery
G
T
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scores for each patient, as determined from secondary ICD-9 disease co-
des.8,9 Excluded from analysis were patients undergoing a bilobectomy
(CPT 32482), lobectomy for a superior sulcus tumor or pulmonary
metastasis (ICD-9 197), lobectomy with a bronchoplastic procedure
(CPT 32486), video-assisted thoracoscopic lobectomy, or lobectomy in
the setting of stage IV NSCLC, such as a patient with an isolated brain me-
tastasis. Also excluded were patients undergoing lobectomy with a primary
ICD-9 code denoting an endobronchial (162.9) or tracheal (162) tumor
component, NSCLC involving multiple lobes of the lung (162.8) or the
chest wall (198.89, 171.4), or a pleura-based neoplasm (163).
Postoperative stay was calculated as the number of days from the day of
surgery until death or discharge. Patients who died after lobectomy did not
have the opportunity for readmission and sowere removed from that portion
of the analysis. Postoperativemorbiditieswere attributed in a binary fashion
by patient, so that a patient who had more than 1 event was only counted
once; however the tabulations of specific categories of complications in-
clude every occurrence. Operativemortalitywas defined as patient death af-
ter surgery before discharge from the hospital or within 30 days of surgery.
Hospital charges represent the total gross charges before any contractual
adjustments and include all postings from the day of surgery through dis-
charge or death. Professional fees were excluded. Parity of hospital charges
was tested by examining each facility’s charge per discharge index; a com-
parison of inpatient charges indexed to discharge diagnoses.10 This is
a method of determining whether different facilities have similar levels
of charges used by the private insurers and the Centers for Medicare and
Medicaid Services.11 Patients transferred between facilities during their lo-
bectomy hospitalization were excluded from eligibility from this study be-
cause of the artifactual change in charges and hospital stay that resulted. A
readmission was attributed to patients designated in either cohort who re-
quired readmission to the hospital within 30 days of discharge from the lo-
bectomy admission; however, charges incurred during the readmission
were not included in the hospital charge calculation for that patient.
The unit of analysis for this study was a patient undergoing lobectomy
for NSCLC. Surgeon specialty was identified as the exposure variable. Dis-
charge versus operativemortality was the primary outcome for the analysis.
Multiple logistic regression analysis was used to study relationships be-
tween patient variables and the identified outcome measures. Regression
models were adjusted for clustering or nesting at the hospital level by the
construction of 2-level hierarchic analysis models with the assumption of
normative distribution of variables.11,12 Group mean centering for each
cohort was used within the analyses. Adjustments within the regression
analysis were made for patient age and Charlson comorbidity index
score and reported as adjusted odds ratios. Hospital and surgeon volume
were then individually adjusted by including a continuous variable
representing each in the regression model and the effect on the primary
outcomes observed.
Bivariate analysis of data was performed with GraphPad Prism software
(version 4.02; GraphPad Software, Inc, San Diego, Calif) for Windows
(Microsoft, Redmond Wash). Differences between categoric variables
were evaluated by the Fisher’s exact test. Differences between continuous
variables were measured by the 2-tailed Student t test or theMann-Whitney
test for nonnormally distributed data. Multivariate analysis was performed
with Stata software (version 11; StataCorp, College Station, Tex).
For the purposes of this investigation, adherence to NCCN guidelines
(Table 2) was defined according to whether pulmonary function testing,The Journal of Thoracic and Ccomputed tomographic imaging of the chest, and staging of the mediasti-
num occurred before surgery. Mediastinal lymph node sampling or dissec-
tion at the time of lobectomy was also required.RESULTS
During the 5-year study period, 2823 lobectomies that
were performed by 46 general surgeons and 3653 lobecto-
mies that were performed by 29 thoracic surgeons at 54 hos-
pitals in 31 states met the entrance criteria for this
investigation (Table 3). This resulted in mean numbers of
lobectomies for general surgeons and thoracic surgeons of
61 and 126, respectively, during the 5-year period. Mean
age and mean Charlson comorbidity index score varied sig-
nificantly between the two patient cohorts. Sex distribution
did not.
The frequencies of patients with pathologic stage I and II
NSCLC were similar between the 2 patient groups; how-
ever, significantly more patients with stage IIIA disease
underwent surgery by a thoracic surgeon, whereas signifi-
cantly more patients with stage IIIB disease underwent sur-
gery in the general surgeon cohort. It was also significantly
more common for patients with stage III NSCLC to receive
neoadjuvant therapy if their care involved a thoracic
surgeon.
Patients operated on by a thoracic surgeon also had a sig-
nificantly higher rate of fulfilling the study’s NCCN criteria.
This finding was true for each of the 4 criteria examined as
well as for the overall category. Similarly significant was
the difference in the number of patients found not to have
a malignancy in the lobectomy specimen in the general sur-
geon group relative to the thoracic surgeon cohort.
Mean hospital stay was significantly longer in the general
surgeon cohort than in the thoracic surgeon cohort. In addi-
tion, the number of patients with a prolonged stay, defined
by Kozower and colleagues11 as longer than 14 days, was
significantly greater in the general surgeon patient cohort.
No significant difference in readmission rates between the
2 groups was found. The difference in stay in the general
surgeon cohort could not be explained solely on the basis
of the differences in operative morbidity and mortality.
The frequency of postoperative morbidities was found to
be significantly higher in the general surgeon patient cohort
than in the thoracic surgeon patient cohort (Table 4). When
individual postoperative events were compared, prolonged
air leak and return to the operating room for bleeding
were found to differ significantly between the 2 patient
groups, with a higher frequency of occurrence in the general
surgeon patient cohort. Operative mortality was also signif-
icantly more frequent in the general surgeon patient cohort.
No variables examined other than surgeon specialty were
found to be predictors for morbidity or mortality after
lobectomy for NSCLC.
After adjustment for the confounding variables of age
and Charlson comorbidity index score, multiple logisticardiovascular Surgery c Volume 145, Number 1 69
TABLE 3. Results of analysis
General
surgeons
Thoracic
surgeons
P
value
N 2823 3653
Age (y, mean  SD) 63  13 67  17 <.0001
Male 1502 (53%) 1932 (53%) .052
Charlson comorbidity index
(mean  SD)
6  3 9  4 <.0001
Pathologic stage
I 1256 (45%) 1399 (38%) .21
II 1077 (38%) 1569 (43%) .08
IIIA 229 (8%) 547 (15%) <.0001
IIIB 261 (9%) 138 (4%) <.0001
National Comprehensive Cancer
Network guideline adherence
1609 (57%) 3142 (86%) <.0001
Computed tomographic imaging 2733 (97%) 3578 (98%)
Pulmonary function tests 1913 (68%) 3199 (88%)
Preoperative mediastinal staging 1621 (57%) 3142 (86%)
Intraoperative mediastinal
staging
1609 (57%) 3321 (91%)
Preoperative chemotherapy or
radiation therapy
26 (0.9%) 467 (13%) <.0001
No malignancy found 257 (9%) 133 (4%) <.0001
Hospital stay (d, mean  SD) 9  11 6  7 <.0001
Prolonged stay 213 (8%) 186 (5%) <.0001
Readmissions 163 (6%) 249 (7%) .09
Charges ($US, mean) $89,000 $78,000 <.0001
Values are numbers and percentages of patients unless otherwise stated. SD, Standard
deviation.
TABLE 1. Availability of data points from the Premier database and
the local hospital’s American College of Surgeons tumor registry
Variable Premier
Tumor
registry
Age x x
Sex x x
Pulmonary function testing x
Computed tomographic imaging of the chest x
Prelobectomy mediastinal staging x x
Neoadjuvant chemotherapy or radiation therapy x x
Intraoperative mediastinal staging x x
Pathologic stage* x
Charlson comorbidity index x
No finding of malignancy after lobectomy x x
Readmission x
Morbidity x
Mortality x x
Charges x
*Staging according to Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti
A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
TABLE 4. Morbidities and operative mortality
General Thoracic P
General Thoracic Surgery Freeman et al
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be independently reduced by 63% (adjusted odds ratio,
0.37; 95% confidence interval 0.13-0.59; P< .0001) for
patients undergoing lobectomy by a thoracic surgeon
when compared with the general surgeon patient cohort.
An analysis adjusting for differences in both hospital and
provider volume found a reduction in mortality; however,
the significant difference remained between the 2 cohorts
(adjusted odds ratio, 0.60; 95% confidence interval
0.53-0.72; P<.0001).
Global parity among individual hospitals with respect
to charges was found, with no significant difference recog-
nized when charges per discharge indexes were compared;
however, a significant difference between mean charges of
$11,000 (14%) was found between the general surgeon and
thoracic surgeon cohorts (P<.0001). An analysis of charge
segregation found that 76% of the differences in mean
chargesbetween thegroupswere directly related to the length
of stay and morbidities in the general surgeon cohort.surgeons surgeons value
Morbidities 310 (11%) 146 (4%) <.0001
Prolonged air leak (>7 d) 136 42 <.0001
Reoperation for bleeding 81 21 <.0001
Pneumonia 32 25 .07DISCUSSION
The concept that formal specialty training produces supe-
rior results for surgical procedures is not a new one. SeveralTABLE 2. Scoring of National Comprehensive Cancer Network
guideline7 adherence
Variable Adherence
Pulmonary function tests
before lobectomy
Results dated before lobectomy
Computed tomographic
imaging before lobectomy
Results dated within 90 d before lobectomy
Prelobectomy mediastinal
staging
Positron emission tomography,
endobronchial ultrasonography,
or mediastinoscopy before lobectomy
70 The Journal of Thoracic and Cardiovascular Surgeinvestigators have found that outcomes after specific surgi-
cal procedures are superior when performed by surgeons
who have undergone an additional formal training period
after general surgery residency relative to general surgeons
who have not done so. Hollenbeak and colleagues2 reported
that patients undergoing carotid endarterectomy by a vascu-
lar surgeon had significantly lower rates of stroke andMyocardial infarction 16 17 .7
Bronchopleural fistula 8 4 .19
Respiratory failure 29 23 .1
Stroke 3 3 .9
Deep vein thrombosis 5 11 .5
Mortality 198 (7%) 73 (2%) <.0001
Myocardial infarction 74 29
Respiratory failure 88 21
Multisystem organ failure or sepsis 24 11
Stroke 12 5
Pulmonary embolus 9 7
Data represent numbers of patients with percentages for overall categories.
ry c January 2013
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tients whose surgery was performed by a general surgeon.
Similarly, Dimick and associates3 found significantly lower
operative mortality after esophagectomy for thoracic sur-
geons relative to general surgeons.
Similar comparisons between cardiothoracic surgeons
and general surgeons for patients undergoing lung cancer
resection have also been published. Silvestri and col-
leagues4 from the Medical University of South Carolina
published what is recognized as the initial modern compar-
ison of the outcomes of lung cancer resection between gen-
eral and cardiothoracic surgeons in 1998. Silvestri and
colleagues4 found a significant reduction in operative mor-
tality for patients undergoing either lobectomy or pneumo-
nectomy performed by a cardiothoracic surgeon rather than
general surgeons across the state of South Carolina; how-
ever, the difference in mortality may have been partially
confounded by the inclusion of pneumonectomies in the
analysis. Furthermore, no attempt to assess tumor staging
was performed, and the study was geographically
isolated.12
Goodney and coworkers5 subsequently published an
analysis of Medicare claims data for the calendar year of
1998, comparing the outcomes of lobectomy or pneumo-
nectomy for lung cancer performed by either a general sur-
geon, a cardiac thoracic surgeon, or a noncardiac thoracic
surgeon. They found significant differences in operative
mortality between cardiac or noncardiac thoracic surgeons
and general surgeons, differences that were in part related
to hospital and surgeon volume. These findings, however,
are tempered by the arbitrary and possibly inaccurate clas-
sification of cardiac versus noncardiac thoracic surgeons,
a lack of inclusion of the stage of malignancy in the analy-
sis, and the use of a single calendar year sample.
Schipper and colleagues1 and Ellis and associates6 have
published the results of 2 retrospective cohort analyses
comparing general surgeons, cardiac surgeons and noncar-
diac thoracic surgeons performing lung resections for lung
cancer. In the 2009 article,1 a significant decrease in the fre-
quency of operative mortality and prolonged stay was found
for cardiac and noncardiac thoracic surgeons relative to
general surgeons; when adjusted for surgeon volume, how-
ever, the difference in operative mortality dissipated.
In the 2011 report,6 the Nationwide Inpatient Sample da-
tabase was once more queried for lung resections for lung
cancer. Again, a significant difference in operativemortality
was found between cardiac and noncardiac thoracic sur-
geons as they were defined in the study relative to general
surgeons (odds ratio, 1.47; P ¼ .003). The investigators
also found that preoperative and intraoperative surgical
staging was significantly more frequent for noncardiac
thoracic surgeons than for either general surgeons or
cardiac thoracic surgeons (73%, 55%, and 54%, respec-
tively; P<.0001), which they hypothesized could explainThe Journal of Thoracic and Csuperior perioperative and long-term outcomes. Although
this study contributed valuable information to this topic,
the assignment of surgeons to specialties without regard
for board certification, a surrogate for a formal training pe-
riod in thoracic surgery, may have confounded the results.
Furthermore, the distribution of operative staging may ex-
plain long-term oncologic outcomes, as hypothesized by
Farjah and associates,13 but it likely does not explain differ-
ences in operative morbidity and mortality.
This investigation sought to analyze the outcomes and
patterns of care of patients undergoing lobectomy for
NSCLC at multiple institutions across a geographically di-
verse health system. The use of the Premier inpatient data-
base allowed all lobectomy procedures within the health
care system, regardless of payer type, to be identified.
This database also allowed patient charges, which have
not been included in previous analyses, to be compared be-
tween the 2 groups. The addition of tumor registry data pro-
vided validation of some aspects of the Premiere data, as
well as allowing the assessment of adherence to national
treatment guidelines in the preoperative evaluation, a factor
that we have previously found to improve the quality of care
of patients with NSCLC.14
This study was also designed to limit operative proce-
dures to lobectomy to minimize differences that could be
expected with lesser procedures, such as nonanatomic
wedge resections, and procedures with higher recognized
rates of morbidity and mortality, such as pneumonectomy.
Video-assisted thoracoscopic lobectomy was also excluded
from this analysis, because the frequency of this procedure
performed by general surgeons in this investigation was ex-
tremely low. Similarly, by limiting inclusion to ICD-9 codes
that should allow resectability without the need for a com-
plex lobectomy, it was anticipated that more uniform co-
horts could be generated for analysis.
The classification of surgeons in this investigation was
not based on their historical case mix but on their Amer-
ican Board of Medical Specialty board certification status.
Board certification in either general or thoracic surgery
should imply a requisite formal training period as well
as some efforts to remain active and current in the spe-
cialty through the maintenance of certification process.
Similarly, we chose not to separate board-certified thoracic
surgeons into cardiac and noncardiac thoracic surgeons.
According to the Thoracic Surgery Workforce Report pub-
lished in 2011,15 the majority of currently practicing tho-
racic surgeons who are not exclusively practicing
congenital cardiac surgery in the United States continue
to perform pulmonary resections, making an extrapolation
of any meaningful results of this analysis to operational or
health policy, difficult. Furthermore, although thoracic sur-
geons can limit their practice to adult cardiac or general
thoracic surgery, there is no external validation of such
a designation.ardiovascular Surgery c Volume 145, Number 1 71
General Thoracic Surgery Freeman et al
G
T
SOn the basis of these study design parameters, an analysis
of nearly 6500 lobectomies for NSCLC found that patients
operated on by a thoracic surgeon were more likely to un-
dergo a preoperative evaluation consistent with national
guidelines and to have a reduced risk of operative morbidity
relative to lobectomies performed by a general surgeons.
Stay and mean hospital charges were also significantly re-
duced in the thoracic surgeon cohort. This is despite the
findings that the thoracic surgeon patient cohort had a higher
mean age, a higher rate of comorbid disease, more use of
neoadjuvant therapy, and more advanced pathologic stage.
A significantly lower rate of operative mortality was also
recognized in the thoracic surgeon patient cohort relative to
the general surgeon patient cohort. This difference persisted
even after adjustment of the analysis for facility or provider
lobectomy volume. This is in contrast to some previous re-
ports, in which adjustments for surgical volume negated the
difference in mortality between similar groups. Possible ex-
planations for these results include the assignment of sur-
geon specialty on the basis of formal training and board
certification, the effect of separating cardiac and noncardiac
thoracic surgeons in other reports, and a lower volume
threshold for facility inclusion used in this review.
In light of the longer mean stay and the higher rate of
postoperative morbidities, it is not surprising that the gen-
eral surgeon patient cohort was found to have a higher
mean hospital charge than that in the thoracic surgeon co-
hort. Seventy-six percent of the difference in mean charges
can attributed to differences in stay and operative morbidity
and mortality. The remaining difference in mean charges
cannot be further defined and is probably related to individ-
ual practitioner variation. The difference in mean charges
was statistically significant and, at a time when hospital
margins of profit commonly range between 3% and 5%,
it is also operationally relevant.
Two other findings in this review raise concern regarding
the adequacy of the preoperative evaluation some general
surgeon patients underwent. Specifically, these include
a higher rate of general surgeon cohort patients having sur-
gery for what proved to be stage IIIB NSCLC and the higher
frequency in the general surgeon patient cohort of surgical
specimens in which no malignancy could be identified.
Both of these findings may relate to the relatively low rates
of computed tomographic and positron emission tomo-
graphic imaging use found in the general surgeon patient
cohort.
This investigation has limitations common to similar
analyses. Specifically, retrospective data are not as accurate
as prospectively collected information. The best source of
data for lobectomy for NSCLC, the Society of Thoracic
Surgeons general thoracic surgery database, does not, how-
ever, include a significant number of surgical procedures
performed by general surgeons to allow such a comparison.
Some also do not consider the database to be reflective of72 The Journal of Thoracic and Cardiovascular Surgethe majority of cardiothoracic surgeons’ practices at present
because of low rates of participation.
Another potential criticism is that the outcome of a surgi-
cal procedure such as a lobectomy is the result of both the
ability of the surgeon and the clinical processes and person-
nel inherent to a facility. Although adjusting the analysis for
facility volume can partially compensate for this effect,
qualitative differences may exist between facilities that do
influence patient care and outcomes as previously shown.16
As Kozower and colleagues17 pointed out, such corrections
are not always appropriate. Similarly, the effect of increas-
ing surgical volume may not be beneficial above a specific
threshold as seen in the work of Finley and associates18 in
their analysis of Canadian hospitals performing lobectomy.
Importantly, Treasure and colleagues19 found that within
the specialty of cardiothoracic surgery volume does not sig-
nificantly influence mortality after lobectomy, implying that
differences found in outcomes between specialties in this
investigation may be independent of volume and related
to the additional training required for board certification
in thoracic surgery. Finally, although they are theoretically
pleasing, such adjustments do not change the fact that what-
ever the cause, patients in the general surgeon cohort face
increased risks of both complications and death when
undergoing lobectomy in the setting analyzed.
CONCLUSIONS
This review found that currently measurable indicators
for quality of care were significantly superior and overall
charges were significantly reduced when a lobectomy for
NSCLC was performed by a cardiothoracic surgeon rather
than by a general surgeon. These finding may have implica-
tions for facility and payer physician credentialing.
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Dr Thomas A. D’Amico (Durham, NC). Dr Freeman, I con-
gratulate you and your colleagues on performing this important
study. Improving the quality of care in the setting of the treatment
of lung cancer should be the most important goal of future systems
of care for cancer, because lung cancer is responsible for more than
a third of all cancer deaths. Adherence to established guidelines,
such as the NCCN guidelines, is the most efficient pathway to
the improvement of outcomes. These guidelines in fact specify
that patients with lung cancer should be treated by lung cancer spe-
cialists; that is, thoracic surgeons. Sadly, that recommendation has
not reached the standard of care status in the United States.
This study, an analysis of more than 6400 patients in a single
health care system, provides more evidence to support the NCCN’s
recommendations. Patients operated on by thoracic surgeons had
significantly lower morbidity and mortality and also shorter stay
despite being older and having a higher Charlson comorbidity in-
dex than patients operated on by general surgeons. As well, pa-
tients whose disease was staged and managed by thoracic
surgeons received better evidence-based care, including preopera-
tive and intraoperative mediastinal staging, all at a lower cost. Al-
though there are acknowledged limitations of an administrative
database analysis, as you outlined, the findings are persuasive;
however, we are not the ones needing persuasion.
Although we would all agree that thoracic surgeons provide su-
perior lung cancer care, does your research indicate that there were
in fact thoracic surgeons whowere not providing quality evidence-
based care in this particular health care system? We will not be
successful in changing paradigms of care if we are seen to be pro-
tecting inferior thoracic surgeons. Analysis of outcomes in the
general thoracic surgery Society of Thoracic Surgeons databaseThe Journal of Thoracic and Csuggests that quality of lung cancer care is not universal in that
database.
Dr Freeman.We were not, by agreement, able to focus on in-
dividual provider results with the health system. So I cannot tell
you Dr X’s mortality versus Dr Y’s, and that was by design.
Dr D’Amico. So you will be seen as protecting inferior thoracic
surgeons. The NCCN guidelines chosen for this study included the
use of computed tomographic scanning and pulmonary function
testing, relatively low thresholds for quality and nearly universally
used by general and thoracic surgeons alike. Are there other pa-
rameters that you could have used or would use in the future to dif-
ferentiate adherence to evidence-based guidelines more
discriminatingly?
Dr Freeman. There certainly are other factors we could use. As
you know, the hardest part of a study like this is not what to include
but what not to include, because it has to be manageable. We chose
what we thought were fairly low bar measures, such as pulmonary
function tests, computed tomographic scan, and staging the medi-
astinum. We gave credit for positron emission tomography and
mediastinoscopy. So we set the bar pretty low intentionally, as
the first step. There are much more complex measures that we
could use, and that may be something to look at in the future.
Dr D’Amico. Can you name what these measures are? What
would you study to actually differentiate quality from not quality
in the future?
Dr Freeman. One of the things I think is important personally,
which is almost impossible to measure, unfortunately, is multidis-
ciplinary care and multidisciplinary care conference planning. We
found that to be extremely effective; transparency, multiple heads
put around the table. It’s very hard to measure though.
Dr D’Amico. Finally, what processes do you recommend to as-
certain that only qualified surgeons are credentialed to manage pa-
tients with lung cancer in the future?
Dr Freeman. Well, I’m the eternal pessimist, so I have con-
cerns that we as a physician group will ever be able to do that.
One of the reasons we included cost in this and one of the reasons
that we looked at a single health system is because I think the
health system eventually will say, ‘‘Here are some data. Show us
that you did additional training to do this procedure or you
shouldn’t be doing it.’’ So I think it will have to be an external locus
of control.
Dr D’Amico. Good paper. Thank you.
Dr Tomasz Grodzki (Szczecin, Poland). I congratulate you.
I also have a short comment. I come from a country where the hos-
pital charge for a lobectomy is US $5000, and mortality and mor-
bidity are exactly the same. The answer is because we convinced
general surgeons in Poland that it’s so complicated and dangerous
to perform lobectomy that they are doing nothing, and 99% of lo-
bectomies in Poland are performed by certified thoracic surgeons.
This is the direction this Society should promote. It’s simply dan-
gerous to refer patients to general surgeons for lobectomy. If we
compare it with the previous lecture by David Jones’s group that
the number of lung cancer cases in teaching hospitals is going
down, the Society should fight for protecting the patients first
and providing the patients with thoracic surgeons second. I think
that the government relations committee or any of the Society
committees should promote these results, because it’s simply ben-
eficial for the patients.ardiovascular Surgery c Volume 145, Number 1 73
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SDr Freeman. Obviously, I agree in principle with your com-
ments. As Dr Krasna would probably tell you, there are a lot of di-
lemmas regarding that kind of an idea. With 85% of cancer care in
the United States occurring outside a National Cancer Institute
cancer center, outside a university system, and geographically
I’m not sure how you would make that work, but I think in princi-
ple you have a valid point.
Dr Mark J. Krasna (Neptune, NJ). Rich, I think it was a great
study. What I enjoyed, kind of looking at this as the other side of
the good paper we heard this morning from UVA, is that since it
was all one health system, although you did blind some of the is-
sues that Tommy and I would have liked to have seen, you really
took a deep dive into the data. So I’ll just ask you the dirty ques-
tion, which is, if you were the vice president of quality assurance
of your health system, why is it when you’re looking at the health
system that so many lobectomies are being done for cancer by
non–board certified thoracic surgeons, when in your health system
you actually have a built-in referral opportunity to actually region-
alize, which most of the hospitals don’t even have that opportunity
across the states?
Dr Freeman. I think it’s multifactorial. Access is an issue. Yes,
there are 76 hospitals in our system. Some are in Idaho, and some
are in Indiana, and some are in Wisconsin. When you look at non-
cardiac thoracic surgeons in 76 hospitals, there are really 4 prac-
tices that have dedicated general thoracic surgeons. The vast
majority of this practice is done by cardiothoracic surgeons. One
thing that I do want to continue to look at and do some subset anal-
ysis on is the size of the hospital and who does the lobectomy. It’s
intuitive, but it’s a general surgeon in a small hospital. Often it’s
not by choice. Often, when I talk to some of these people,
it’s the administration who actually wants them to do that case.
So it’s very complex.
Dr David M. Follette (Sacramento, Calif). I’ve been on a num-
ber of credentialing committees. The problem is that when they
credential general surgeons, they look at their training and then74 The Journal of Thoracic and Cardiovascular Surgethey compare their numbers to the numbers that the American
Board of Thoracic Surgery requires. For example, a number of
years ago, the Board required 20 lobectomies. If a general surgeon
documented 20 lobectomies, the credentials committees were in
a very difficult position to deny them privileges. So the question
is, in your regional system, how do you think you could get around
this?
Dr Freeman. And that may work in our favor now. As most of
you know, the general surgical residency training has changed
significantly since most of us were general surgeons. Where
senior level residents did a lot of noncardiac thoracic surgery,
a lot of that has gone away; the requirements are much lower,
and I think most general surgeons now come out with much
less experience than they did 20 years ago in noncardiac
thoracic surgery, unless they are very interested, at least in my
experience.
Dr Stephen D. Cassivi (Rochester, Minn). Richard, I congratu-
late you. I think this is going to be an oft-quoted paper. Clearly,
you’re preaching to the converted here, and this is a message
that needs to go beyond this room.
The argument countering your findings will be that you’re
a general thoracic surgeon and you’re going to be biased. I just
wanted to emphasize that I think you have bent over backwards
to be fair in the construction of your comparison. You have com-
pared open lobectomy with open lobectomy, whereas, as we know
that video-assisted thoracoscopic surgical lobectomies are grow-
ing in number and are much more likely within the population
of general thoracic surgeons. So your length of stay, your comor-
bidities, and your cost would likely show an even at a greater dis-
parity if you were to compare general thoracic surgeons with
general surgeons. It’s more of a comment than a question, but I
think it’s something that we all need to underline as we go
forward with these new data. Thanks very much for your
presentation.
Dr Freeman. I think that’s an excellent point.ry c January 2013
